AOD-9604: Research Overview

AOD-9604 is a modified peptide fragment corresponding to amino acids 177–191 of the C-terminus of human growth hormone (hGH), with an additional tyrosine residue at the N-terminus to facilitate detection. It was developed by Metabolic Pharmaceuticals (now Calzada) as a candidate obesity drug with the hypothesis that the lipolytic activity of hGH could be isolated from its growth-promoting and diabetogenic effects. This overview summarizes the research evidence, the clinical program, and the honest limitations of the compound’s history.

What Is AOD-9604?

Human growth hormone exerts pleiotropic effects: it stimulates growth, increases lean body mass, promotes lipolysis, and can raise blood glucose. Researchers at Monash University identified that the C-terminal region of hGH — specifically the fragment spanning residues 176–191 — retained lipolytic activity in adipocytes but did not bind the growth hormone receptor and therefore lacked the growth-promoting and hyperglycemic effects of intact hGH.

AOD-9604 has a molecular weight of approximately 1,815 Da and a plasma half-life of roughly 30 minutes. It is distinct from HGH Fragment 176-191 (which lacks the N-terminal tyrosine) though the two are closely related and often discussed interchangeably in the research literature.

Mechanism of Action

AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat synthesis) in adipocytes through a mechanism that does not involve the growth hormone receptor (GHR). The precise receptor or binding site remains incompletely characterized. Studies by Heffernan and colleagues at Monash University demonstrated that AOD-9604 and full-length hGH both increase fat oxidation and reduce adipose mass in obese mice, and that these effects correlate with upregulation of beta-3 adrenergic receptor (beta-3-AR) expression in adipose tissue, though the lipolytic effect is not directly mediated through beta-3-AR.

Unlike full-length hGH, AOD-9604 does not raise blood glucose, does not stimulate IGF-1 production, and does not induce cell proliferation in in vitro assays. This differentiated profile was the basis for its clinical development.

What the Research Shows

Preclinical Studies

The foundational preclinical studies by Heffernan et al. at Monash University established that AOD-9604 reduced body weight and increased fat oxidation in obese (ob/ob) mice in a 14-day chronic treatment study (PMID 11673763). A follow-up study examined the role of beta-3-AR in mediating these effects using knockout mice and confirmed that while beta-3-AR expression was upregulated by AOD-9604, the direct lipolytic action did not require beta-3-AR (Heffernan et al., Endocrinology, 2001; published as PMID 11606554 at Oxford Academic).

Early Human Studies

Ng et al. (J Endocrinol, 2000; PMID 10950816) published data on oral administration of a synthetic hGH C-terminal fragment in humans, demonstrating dose-dependent alterations in lipid metabolism. This was among the first human data suggesting biological activity of this peptide class. However, the doses, formulation, and compound used in this early work differed from the AOD-9604 compound subsequently taken into later-phase trials.

Phase 2 Clinical Trials and Discontinuation

Metabolic Pharmaceuticals advanced AOD-9604 into phase 2 clinical trials for obesity in humans in the early-to-mid 2000s. Multiple trials were conducted at different doses and routes of administration. The results were equivocal: while early phase 2 data showed some signals of weight loss activity, larger or longer studies did not demonstrate clinically meaningful effects on body weight compared to placebo. The clinical development program was ultimately discontinued, and AOD-9604 did not progress to phase 3 trials or regulatory submission for an obesity indication. The compound did receive Generally Recognized As Safe (GRAS) status from a US consulting firm for use in food products, but this is distinct from FDA drug approval.

It is important to be direct about this history: AOD-9604 did not succeed as a pharmaceutical obesity drug. The preclinical promise did not translate into robust efficacy in human clinical trials. This is a common outcome in obesity pharmacology and should be factored into any assessment of this compound.

Pharmacokinetics

AOD-9604 has a plasma half-life of approximately 30 minutes following subcutaneous administration. Its molecular weight is approximately 1,815 Da. It does not bind the hGH receptor and is therefore not expected to produce GH-axis effects. Formal published human pharmacokinetic studies are limited; the phase 2 clinical trial publications available in peer-reviewed literature do not provide comprehensive PK parameters. Lyophilized: stored at −20 °C; reconstituted at 2–8 °C for up to 28 days.

Common Research Dose Ranges

DISCLAIMER: The following dose ranges are drawn from published preclinical and early-phase clinical research literature and are provided for informational and research reference purposes only. They are not medical advice, prescribing guidance, or a recommendation to use this compound. AOD-9604 has not received FDA approval.

Preclinical murine studies used daily subcutaneous administration across a range of doses. The Heffernan et al. (2001, PMID 11673763) study used chronic subcutaneous delivery via osmotic pumps in obese mice. Early human phase 2 trials tested AOD-9604 at daily subcutaneous doses in the range of 250 mcg to 1,000 mcg according to contemporary reports and FDA GRAS filings, though complete peer-reviewed dose-response data from the phase 2 program is not comprehensively available in the published literature.

Storage

Lyophilized AOD-9604 should be stored at −20 °C. Reconstituted solutions should be kept at 2–8 °C and used within 28 days. The compound should not be frozen post-reconstitution.

What AOD-9604 Is NOT

AOD-9604 is not human growth hormone and does not bind the GH receptor. It does not stimulate IGF-1 production, promote tissue growth, or exert anabolic effects. It is not FDA-approved for any indication. Despite its preclinical promise, it failed to demonstrate sufficient clinical efficacy to advance through phase 2 trials for obesity — a fact that distinguishes it from more extensively validated weight management compounds. GRAS status for food use is a safety designation, not an efficacy or drug approval.

References

See citations below.